Hertzel C Gerstein Selected Research

2,4-thiazolidinedione (thiazolidinedione)

10/2010	Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.
3/2010	Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial.
3/2010	Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy.
6/2009	Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone).
12/2008	Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hertzel C Gerstein Research Topics

Disease

94	Type 2 Diabetes Mellitus (MODY) 10/2022 - 03/2002
37	Cardiovascular Diseases (Cardiovascular Disease) 10/2021 - 01/2002
24	Glucose Intolerance 01/2022 - 02/2003
21	Heart Failure 09/2022 - 03/2003
20	Myocardial Infarction 10/2021 - 09/2002
19	Stroke (Strokes) 01/2022 - 09/2002
15	Hypoglycemia (Reactive Hypoglycemia) 01/2021 - 07/2005
15	Insulin Resistance 01/2020 - 01/2002
11	Cognitive Dysfunction 01/2022 - 10/2013
8	Acute Coronary Syndrome 01/2022 - 11/2008
8	Hypertension (High Blood Pressure) 01/2021 - 01/2002
7	Obesity 01/2021 - 06/2008
7	Renal Insufficiency (Renal Failure) 01/2020 - 01/2002
7	Neoplasms (Cancer) 12/2019 - 12/2007
6	Body Weight (Weight, Body) 01/2022 - 02/2007
6	Dyslipidemias (Dyslipidemia) 01/2020 - 01/2003
6	Weight Gain 10/2018 - 02/2007
5	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2021 - 07/2010
5	Diabetes Mellitus 07/2015 - 07/2005
5	Atherosclerosis 09/2013 - 12/2008
5	Proteinuria 06/2010 - 03/2003
4	Chronic Renal Insufficiency 01/2022 - 12/2017
4	Unstable Angina 01/2022 - 12/2015
4	Hyperglycemia 12/2021 - 11/2007
4	Kidney Diseases (Kidney Disease) 10/2021 - 05/2009
4	Vascular Diseases (Vascular Disease) 01/2021 - 03/2003
4	Albuminuria 01/2021 - 03/2003
4	Metabolic Syndrome (Dysmetabolic Syndrome X) 05/2015 - 01/2011
3	Diabetic Nephropathies (Diabetic Nephropathy) 01/2022 - 02/2013
3	Dementia (Dementias) 01/2022 - 01/2014
3	Coronary Artery Disease (Coronary Atherosclerosis) 01/2022 - 12/2008
3	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 12/2021 - 07/2005
3	Coronary Disease (Coronary Heart Disease) 01/2020 - 11/2017
3	Weight Loss (Weight Reduction) 12/2019 - 08/2013
3	Inflammation (Inflammations) 01/2019 - 01/2007
3	Hyperkalemia 02/2013 - 01/2002
2	Pancreatitis 10/2021 - 12/2015
2	Pancreatic Neoplasms (Pancreatic Cancer) 10/2021 - 12/2015
2	Hypotension (Low Blood Pressure) 01/2021 - 02/2013
2	Chronic Disease (Chronic Diseases) 01/2019 - 01/2014
2	Genetic Risk Score 11/2018 - 01/2018
2	Prediabetic State (Prediabetes) 01/2018 - 07/2015
2	Chronic Kidney Failure (Chronic Renal Failure) 01/2017 - 11/2003
2	Eye Diseases (Eye Disease) 07/2014 - 05/2009

Drug/Important Bio-Agent (IBA)

63	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 03/2002
36	Insulin (Novolin)FDA Link 10/2022 - 03/2005
26	Insulin Glargine (Lantus)FDA Link 01/2022 - 11/2007
13	CreatinineIBA 01/2022 - 01/2002
11	LipidsIBA 01/2020 - 01/2007
11	Ramipril (Altace)FDA LinkGeneric 07/2015 - 01/2002
10	Metformin (Glucophage)FDA LinkGeneric 01/2022 - 07/2010
10	Rosiglitazone (Avandia)FDA Link 03/2011 - 10/2006
9	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2021 - 03/2002
9	dulaglutideIBA 01/2021 - 01/2018
8	Glucagon-Like Peptide-1 ReceptorIBA 01/2022 - 01/2019
7	Glucagon-Like Peptide 1 (GLP 1)IBA 10/2021 - 01/2018
7	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 01/2018 - 07/2012
7	Nicotine FDA Link 09/2012 - 06/2007
6	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2015
6	lixisenatideIBA 01/2022 - 05/2015
6	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2020 - 06/2007
5	omega-Chloroacetophenone (Mace)IBA 01/2022 - 11/2020
5	2,4-thiazolidinedione (thiazolidinedione)IBA 10/2010 - 12/2008
4	AlbuminsIBA 01/2022 - 12/2006
4	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2022 - 01/2021
4	efpeglenatideIBA 01/2022 - 01/2021
4	Pharmaceutical PreparationsIBA 01/2021 - 01/2014
4	IncretinsIBA 11/2020 - 01/2018
4	Fibric Acids (Fibrates)IBA 01/2020 - 06/2007
4	Fenofibrate (CiL)FDA LinkGeneric 01/2020 - 04/2010
4	Hypoglycemic Agents (Hypoglycemics)IBA 01/2019 - 03/2002
4	Blood Glucose (Blood Sugar)IBA 01/2018 - 07/2010
4	hydroxide ionIBA 04/2014 - 06/2010
4	Vitamin D FDA LinkGeneric 04/2014 - 06/2010
4	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 02/2013 - 01/2002
4	candesartanIBA 08/2009 - 07/2005
3	Natriuretic PeptidesIBA 01/2022 - 05/2017
3	Acarbose FDA LinkGeneric 01/2020 - 01/2017
3	HDL CholesterolIBA 01/2017 - 11/2014
3	Triglycerides (Triacylglycerol)IBA 01/2017 - 11/2014
3	ThiazolidinedionesIBA 10/2010 - 03/2010
2	Advanced Glycation End ProductsIBA 01/2022 - 01/2022
2	LDL CholesterolIBA 01/2022 - 03/2014
2	pro-brain natriuretic peptide (1-76)IBA 01/2022 - 05/2017
2	Thyroid HormonesIBA 01/2021 - 08/2004
2	Testosterone (Sustanon)FDA Link 10/2020 - 01/2019
2	C-PeptideIBA 01/2020 - 03/2010
2	GlucosidasesIBA 01/2020 - 11/2017
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2020 - 07/2015
2	Retinaldehyde (Retinal)IBA 01/2018 - 01/2017
2	Telmisartan (Micardis)FDA Link 07/2015 - 03/2009
2	ProinsulinIBA 05/2015 - 03/2010

Therapy/Procedure

38	Therapeutics 01/2022 - 08/2004
21	Glycemic Control 01/2022 - 03/2002
4	Injections 01/2022 - 07/2005
4	Subcutaneous Injections 01/2021 - 01/2018
2	Renal Replacement Therapy (Therapies, Renal Replacement) 10/2021 - 01/2020
2	Secondary Prevention 01/2021 - 11/2017
2	Light Coagulation 01/2017 - 07/2010
2	Vitrectomy 01/2017 - 07/2010